Skip to main content
. 2022 Jul 28;13:968729. doi: 10.3389/fimmu.2022.968729

Figure 4.

Figure 4

The subgroup analysis between ATB use and cancer prognosis (OS + PFS) of RCC and NSCLC cancer patients treated with ICIs. (A) The relationship between ATB use and OS of NSCLC patients treated with ICIs. (B) The relationship between ATB use and PFS of RCC patients treated with ICIs. (C) The relationship between ATB use and OS of esophagus cancer patients treated with ICIs. (D) The relationship between ATB use and OS of melanoma patients treated with ICIs. (E) The relationship between ATB use and PFS of NSCLC patients treated with ICIs. (F) The relationship between ATB use and PFS of RCC patients treated with ICIs.